Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema
The Pharma Data
JUNE 15, 2025
launch in 2027 — a significant milestone in its mission to bring forward a one-time, potentially curative treatment for hereditary angioedema. Furthermore, Intellia plans to submit a biologics license application (BLA) in 2026 in support of a potential U.S.
Let's personalize your content